ASCO 2020：11项中国研究跻身口头报告，17项Poster报告

所致全球从新冠疫情阻碍，预定于5同年29日~6同年2日在芝加哥开幕的英美两国外科学术委员但会（ASCO）年但会本年度将首次以两条路线上形式举办，这是目前最大规模的两条路线上盛但会。今天，联席但会议的概述作文公告，合计103个sessions，之中国仅有11项学术研究荣膺口头报告，17项荣膺Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

衍生命体替尼或佩佩替尼加卡培他鹿岛用作HER2+前列腺恶普遍性肿瘤乳腺恶普遍性肿瘤（PHOEBE）：一项III期随机试验中。

大舞台：前列腺恶普遍性肿瘤乳腺恶普遍性肿瘤

创作者：之该中心病房徐兵河学术研究员、马飞学术研究员，华东师范大学附属病房胡夕春学术研究员等

概述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可动手术三比如说乳腺恶普遍性肿瘤标准放射治疗后卡培他鹿岛维持节拍放射治疗的III期试验中（SYSUCC-001）。

大舞台：乳腺恶普遍性肿瘤—大面积/范围/主要用途放射治疗

创作者：之永康大学公合计卫生之范围内王树森学术研究员等

概述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

来进行前列腺恶普遍性肿瘤脑组织的表型特质来预测脑组织脊液之中气化DNA检测的概率: 从新工具对抗据闻劲敌

大舞台：从新工具解决据闻问题

创作者：郑美芹 郑德兰等

概述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

塔纳非尼对马利拉非尼作为后期肝蛋白质恶普遍性肿瘤的一两条路线放射治疗：一项对外开放ID、随机、多之范围内II/III期试验中。

大舞台：呼吸道恶普遍性肿瘤—大肠输尿管、肝脏和绝

创作者：四川大学棱果病房毕锋学术研究员、之中国暴政解放军八一病房秦叔逵学术研究员等

概述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

之中国后期肝恶普遍性肿瘤高血压阿帕替尼三两条路线放射治疗：一项随机、安慰剂对照、实验组III期学术研究

大舞台：呼吸道恶普遍性肿瘤—大肠输尿管、肝脏和绝

创作者：之中国暴政解放军八一病房秦叔逵学术研究员、四川大学棱果病房郑秋学术研究员等

概述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后期入院普遍性卵巢恶普遍性肿瘤二次蛋白质减灭术的一项随机III期试验中：SOC1 / SGOG-OV2。

专刊：妇科恶普遍性肿瘤症

创作者：华东师范大学附属之永康病房臧荣余学术研究员等

概述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈恶普遍性肿瘤根治普遍性乳腺矫正后主要用途放射治疗之中的序贯放放射治疗对比实际上恶性肿瘤或同步放放射治疗（STARS学术研究）：一项随机、对照、对外开放ID的III期试验中。

联席但会议：妇科恶普遍性肿瘤症

创作者：之永康大学公合计卫生之范围内白云学术研究员、刘继红学术研究员等

概述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：主要用途吉非替尼对比放射治疗用作可切除的EGFR突变的N1-N2期NSCLC-随机III期外科试验中的再一总体穴居量化。

专刊：肺恶普遍性肿瘤—非小蛋白质大面积-范围/小蛋白质/其他胸部

创作者：佛山市暴政病房吴一龙学术研究员等

概述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变寡集中于非小蛋白质肺恶普遍性肿瘤高血压一两条路线乙酰激酶药物建立联系或不建立联系大力前两条路线大面积恶性肿瘤：III期对外开放ID外科随机试验中（SINDAS）的之末结果（NCT02893332）。

专刊：肺恶普遍性肿瘤-非小蛋白质集中于

创作者：乐山市暴政病房曾铭学术研究员等

概述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对一般而言遇害-1（PD-1）的人源化IgG4单克隆抗体建立联系阿昔替尼用作前列腺恶普遍性肿瘤黏膜胃癌高血压的Ib期学术研究的总穴居期和生命体标志物量化。

专刊：胃癌/恶普遍性肿瘤

创作者：北京大学病房郭军、盛锡楠学术研究员等

概述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全普遍性和结果：通用CAR-T蛋白质首次人体试验中放射治疗入院/难治普遍性T蛋白质急普遍性淋巴蛋白质肺炎（r/r T-ALL）的安全普遍性和。联席但会议：开发计划之中的放射治疗应用-免疫放射治疗。创作者：王欣欣等概述：3013名片：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利抗病毒在后期输尿管楔形蛋白质恶普遍性肿瘤高血压之中的应用：一项随机的对外开放IDII期试验中（ORIENT-2）。联席但会议：呼吸道恶普遍性肿瘤-大肠输尿管恶普遍性肿瘤、肝脏恶普遍性肿瘤和绝道恶普遍性肿瘤创作者：徐建明学术研究员等概述：4511名片：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D抗原CAR-T蛋白质对髓母蛋白质瘤的造成危害普遍性放射治疗联席但会议：之神经递质创作者：代红久、孙斌、杨东、徐晖、朱结缘、魏佳、陈旭东概述：2522名片。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后期错配修复缺陷高血压之中的应用联席但会议：开发计划之中的放射治疗学-免疫放射治疗创作者：沈琳学术研究员等概述：3021名片。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART放射治疗入院/难治普遍性ACUTE淋巴蛋白质肺炎/淋巴瘤的首开人体外科试验中联席但会议: 开发计划普遍性放射治疗学-免疫放射治疗创作者简介：张明志，杨林等概述：3026名片: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）建立联系应用作后期实体瘤高血压的Ib期学术研究联席但会议：发展普遍性放射治疗学--分子类似物药物和药理学创作者：龚继芳，沈琳学术研究员等概述：3523名片：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin建立联系紫杉醇和nedaplatin放射治疗入院普遍性或前列腺恶普遍性肿瘤输尿管楔形蛋白质恶普遍性肿瘤（ESCC）高血压的II期学术研究。联席但会议：呼吸道恶普遍性肿瘤-大肠输尿管、肝脏和绝道恶普遍性肿瘤的学术研究创作者：王志爆冷，郑玉红，王德申，王凤华，任超，谭琼 王志爆冷、郑玉红、王德深、王凤华、任超、谭琼概述：4522名片：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.联席但会议：呼吸道恶普遍性肿瘤-大肠输尿管恶普遍性肿瘤、肝脏恶普遍性肿瘤和绝管恶普遍性肿瘤的三两条路线放射治疗创作者：宋艳等概述：4524名片：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体内环RNA特质向量用作初始活检时检测高等级恶普遍性肿瘤的尿液外体内环RNA特质向量：一项多之范围内的回顾普遍性学术研究联席但会议：泌尿系统循环系统恶普遍性肿瘤症---恶普遍性肿瘤、睾丸恶普遍性肿瘤和恶普遍性肿瘤创作者简介：Liaoyuan Li等概述：5522名片。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 大面积后期宫颈恶普遍性肿瘤并发放射治疗后的主要用途放射治疗联席但会议: 妇科恶普遍性肿瘤症创作者简介： 郑珉珉等概述：6031名片：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼放射治疗睾丸髓普遍性恶普遍性肿瘤的相关普遍性：基于ALTER01031试验中的量化。但会话：肩部创作者：天津市病房得意学术研究员概述：6526名片。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年纪对安洛替尼放射治疗后高血压整部的阻碍: ALTER01031的亚组量化联席但会议：肩部创作者：天津市病房得意学术研究员概述：6527名片。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA量化预测I-IIIA期非小蛋白质肺恶普遍性肿瘤（NSCLC）高血压术后入院: GASTO1035和GASTO1018的结果联席但会议：肺恶普遍性肿瘤-非小蛋白质大面积-范围普遍性/小蛋白质/小蛋白质/其他胸科恶普遍性肿瘤症创作者：Si-Yu Wang等概述：9023名片：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白质肺恶普遍性肿瘤（NSCLC）之中EGFR乙酰激酶药物的从新型病毒性机制联席但会议:肺恶普遍性肿瘤-非小蛋白质前列腺恶普遍性肿瘤肺恶普遍性肿瘤创作者简介：陈昕，金艾利，满宇，欧名妓，湛，薛武，杨少，范敏 陈昕、金艾利、满宇、欧名妓、湛、薛武、杨绍、范敏概述：9528名片：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验中之中后期胃癌总穴居的替代终点站联席但会议：胃癌/恶普遍性肿瘤创作者：聂润聪，袁书爆冷，郑元芳，陈英波，周志伟 聂润聪、袁书爆冷、郑元芳、陈英波、周志伟概述：10030名片：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼放射治疗入院或前列腺恶普遍性肿瘤原发普遍性恶普遍性骨高血压的II期学术研究联席但会议： 肉瘤创作者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、英宗、蔡启庆、涂崇奇、范正福、杨瑶概述：11525名片。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 可行性口碑安罗替尼在后期肉瘤高血压多两条路线放射治疗之中的安全普遍性和。联席但会议：肉瘤创作者：姚伟涛，于是就爆冷，张瑞，王欣，杜从新辉，田志浩，牛晓颖 姚伟涛、于是就爆冷、张瑞、王鑫、杜鑫辉、田志超、牛晓英概述：11526名片：414